Market & News

Dear Members,

Your Board of Directors have pleasure in presenting the Twenty-Fourth Annual Report of Jupiter Life Line Hospitals Limited ("Jupiter" or "Company" or "Your Company") on the business and operations of your Company along with the audited Financial Statement (Standalone and Consolidated Financial Statements) and the Auditors' Report thereon for the Year ended 31st March, 2026.

The Company's standalone and consolidated performance during the financial year ended 31st March, 2026, as compared to the previous financial year, is summarised below:

Amounts in Million

During the year under review the total income of the Company has increased to ' 12,398.75 Million in FY 2025-26 from ' 10,881.36 Million in FY 2024-25, the profit after tax to ' 1913.80 Million in FY 2025-26 from ' 1,847.02 Million in FY 2024-25.

During the year under review the total income of the Company has increased to ' 15,421.55 Million in FY 2025-26 from ' 13,307.49 Million in FY 2024-25, the profit after tax to ' 1941.87 Million in FY 2025-26 from ' 1,937.54 Million in FY 2024-25.

There has been no change in the nature of business carried on by your Company or its subsidiaries during the year under review.

During the year FY 2025-26, the paid-up Equity Share Capital of the Company is ' 65,56,60,220 divided into 6,55,66,022 equity shares of face value ' 10/- each.

The Company proposes to transfer ' 191.38 Million to the General Reserve out of amount available for appropriation, and an amount of ' 1,658.77 Million is proposed to be retained in profit and loss account.

Pursuant to the requirements of Regulation 43A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), the Dividend Distribution Policy of the Company is available on the Company's website at https:// www.iupiterhospital.com/wp-content/uploads/2023/12/ Dividend-Distribution-Policy-v2.pdf

Based on the Company's performance and factors enunciated in the dividend distribution policy your Company is pleased to inform that the Board of Directors of the Company at its Meeting held on 15th May, 2026 had declared the Interim Dividend of Re. 1 per equity share (@10%) on a face value ' 10/- per share.

During the year under review, your Company was not required to transfer any funds to Investor Education and Protection Fund (IEPF).

During the year ended 31st March, 2026 the Company has three subsidiary companies out of which Jupiter Hospital Projects Private Limited is a Material Subsidiary within the meaning of Material Subsidiary as defined under the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ("the Listing Regulations") as amended from time to time. As per the requirement of the Act and SEBI Listing Regulations, your Company has approved a policy for determining material subsidiaries and the same is available on the Company's website at https://www. jupiterhospital.com/Policy-for-Determination-of-Material- Subsidiaries.pdf.

In accordance with Section 129(3) of the Act, a separate statement containing the salient features of the financial statements of all subsidiaries and associate companies/ joint ventures, if any, in prescribed Form AOC - 1 is set out in Annexure III and forms an integral part of this Report. The statement also provides details of performance and financial position of each of the subsidiaries.

The audited financial statements together with related information and other reports of each of the subsidiary companies are available on the Company's website at https://www.jupiterhospital.com/annual-report/ and the same are also available for inspection by the Members.

The brief details of all the subsidiary companies are as follows:

JHPPL is Material Subsidiary of the Company incorporated under the Companies Act, 1956 on 12th October, 2011. Its CIN is U74900MP2011PTC054377 and its registered office is situated at Vishesh Jupiter Hospital, Scheme No. 94, Sector No. 1, Ring Road, Near Teen Imli Square, Indore - 452 020, Madhya Pradesh, India. The Company is holding 96.56% of equity share of JHPPL along with its nominee shareholders.

MHPL is a wholly owned subsidiary of the Company incorporated under the Companies Act, 2013 on 29th June, 2022. Its CIN is U85300MH2022PTC385705 and its registered office is situated at 1004, 360 Degree Business Park, Next to R Mall, LBS Marg, Mulund, Mumbai - 400080, Maharashtra, India. The Company is holding 100% of equity share of MHPL along with its nominee shareholders.

During the financial year under review, pursuant to the approval by the Board of Directors of the Company and MHPL, a whole owned subsidiary, an application has been filed before the Hon'ble National Company Law Tribunal, Mumbai ("NCLT") for amalgamation. All the requisite documents have been submitted to the applicable regulatory. The application is pending for approval of NCLT.

J HP is a subsidiary company incorporated under the Companies Act, 2013 on 2nd March, 2025. Its CIN is U46497MH2025PTC441784 and its registered office is situated at Jupiter Hospital Building, Eastern Express Highway, Thane - 400601, Maharashtra, India. The Company is holding 95% of equity share of JHP along with its nominee shareholders.

Other than disclosed above your Company does not have any other subsidiary company. Further, your Company does not have any associate Company or Joint Venture for the year ended 31 st March, 2026.

Your Company strives to adopt best practices for the effective functioning of the Board and believes in maintaining a diverse Board to create greater stakeholder value and ensure strong corporate governance. The Board of Jupiter comprises experienced and respected professionals who bring valuable expertise, strategic guidance, and leadership.

As on 31st March, 2026, the Board of Directors consists of two Executive Directors, two Nonexecutive Directors and five Independent Directors (including two Women Independent Directors). The details of the composition of Board of Directors are mentioned in the Corporate Governance Report forming part of the Annual Report.

Dr. Ajay Thakker (DIN: - 00120887), Chairman & Managing Director retires by rotation at the ensuing Annual General Meeting and being eligible, offer himself for reappointment. Based on the performance evaluation and recommendation of the Nomination and Remuneration Committee, the board recommends his re-appointment.

1. Dr. Ankit Thakker was appointed as Joint Managing Director at the Annual general Meeting held on 11th July, 2025

2. Mr. Harshad Purani, was designated as a CFO upto 12th May, 2025.

3. Mr. Sivasis Sen appointed as a CFO w.e.f 12th May, 2025.

The Company has received the necessary declarations from each of the Independent Director under Section 149(7) of the Act, stating that he/she meets the criteria of independence laid down in Section 149(6) of the Act and Regulation 25(8) of the SEBI Listing Regulations and there has been no change in the circumstances which may affect their status as independent director during the year. The Independent Directors have also confirmed compliance with the provisions of rule 6 of Companies (Appointment and Qualifications of Directors) Rules, 2014, as amended, relating to inclusion of their name in the databank of independent directors. The Board has taken on record these declarations after undertaking the due assessment of the veracity of the same.

Also, the Independent Directors have complied with the Code for Independent Directors prescribed in Schedule IV of the Act and have confirmed that they are in compliance with the Code of Conduct for Directors and Senior Management personnel formulated by the Company.

Based on the declaration received from all the Independent Directors and in the opinion of the Board, all Independent Directors possess integrity, expertise, experience and proficiency and are independent of the management.

During the year under review, none of the Independent Directors of the Company has had any pecuniary relationship or transactions with the Company, other than sitting fees.

The terms and conditions of appointment of Independent Directors are placed on the website of the Company at https://www.jupiterhospital.com/codes- and-policies/

Pursuant to the provisions of the Companies Act, 2013 and Regulation 17 and 19 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, the Board of Directors ('Board') has carried out an annual evaluation of its performance and that of its individual Directors.

Your Company believes that the process of performance evaluation at the Board level is pivotal to Board Engagement and Effectiveness. The policy and criteria for Board Evaluation are duly approved by NRC. The performance evaluation of Non-Independent Directors and Board as a whole, its committees, and the Chairman of the Company was also carried out by the Independent Directors at a separate meeting of the Independent Directors. The evaluation of Independent Directors was carried out by the entire Board of Directors, excluding the Director being evaluated.

The Board evaluation was conducted through questionnaire designed with qualitative parameters and feedback based on ratings. The criteria for performance evaluation of the Board included aspects like Board composition and structure; effectiveness of Board processes, information and functioning etc. The overall outcome of the performance evaluation for the year was positive with the Board identifying key areas for focus going forward and improving Board effectiveness.

A separate meeting of the Independent Directors without the presence of the Chairman, the Managing Director or other Non-Independent Director(s) or any other Management Personnel was held on 30th January, 2026. The Independent Directors reviewed the performance of Non-Independent Directors, Committees of the Board and the Board as a whole along with the performance of the Chairman of the Company and assessed the quality, quantity and timeliness of flow of information between the management and the Board that is necessary for the Board to effectively and reasonably perform their duties.

Your Company has in place a structured induction and familiarisation programme for its directors, aimed at enabling them to effectively discharge their roles and responsibilities. At the time of appointment, Directors receive a Letter of Appointment setting out in detail, the terms of appointment, duties, responsibilities, obligations, Code of Conduct for Prevention of Insider Trading and Code of Conduct applicable to Directors, Key Managerial Personnel and Senior Management Personnel.

Independent Directors are also appraised on all business- developments and new projects of the Company. Independent Directors are also encouraged to visit the facilities of the Company, new hospital visit and interact with senior management to gain deeper insights into the Company's operations and governance processes. Regular presentations and updates on relevant statutory changes encompassing important laws are made and circulated to the Directors. The details of familiarisation programme held during the year ended 31st March, 2026 is available on the website of the Company at https://www.jupiterhospital.com/ Familiarisation-Programme-2025-26.pdf These familiarisation programmes enable the Independent Directors to develop a comprehensive understanding of the Company's business model, strategy, industry dynamics, organisational structure, and risk management practices, thereby facilitating their effective participation in the Board's deliberations. The policy on the familiarisation programmes imparted to the Independent Directors is s is posted on the website of the Company and may be accessed at: https:// www.jupiterhospital.com/codes-and-policies/

As required by Regulation 34(2) of the Listing Regulations, a Management Discussion and Analysis Report forms part of this Report. The state of the affairs of the business along with the financial and operational developments have been discussed in detail in the Management Discussion and Analysis Report.

A Business Responsibility and Sustainability Report, detailing the various initiatives taken by your Company on the environmental, social and governance (ESG Parameters, forms an integral part of this Annual Report.

The Company is committed to the highest standards of Corporate Governance and firmly believes that sound governance practices are essential for enhancing longterm shareholder value and safeguarding stakeholders' interests. The Company's governance framework is built on the principles of integrity, transparency, accountability, and professionalism, supported by robust systems for effective control and management of its affairs.

The Board of Directors of the Company is committed to adopt the best practices of corporate governance and constant review of the Board processes, practices and the management systems is to maintain a greater degree of responsibility and accountability.

The Corporate Governance report is appended herewith as Annexure I and forms part of this Report.

The compliance certificate from the Practising company Secretary regarding compliance of conditions of Corporate Governance is appended herewith as Annexure II and forms part of this Report.

The Board of Directors of the Company has adopted a Code of Conduct and the same has been hosted on the Company's website at https://www.jupiterhospital.com/ Code-Of-Conduct.pdf.

The Directors and senior management personnel have affirmed their compliance with the Code for the year ended 31st March, 2026.

During the year under review Four (4) Board of Directors meetings were held. Details relating to the meetings, including attendance and other relevant information, are provided in the Corporate Governance Report forms a part of the this Report.

All meetings were duly constituted with the required quorum, and the gap between consecutive meetings remained within the prescribed limit of 120 days, in compliance with applicable laws and regulations.

Further, the details of composition of the committees, dates of the meeting of the committee, attendance at the meeting and other details are given in the Report on Corporate Governance Report forms a part of the this Report.

The Members of the Company at the 20th Annual General Meeting had appointed M/s. Aswin P. Malde & Co., Chartered Accountants (Firm Registration No. 100725W), as Statutory Auditors of the Company for a term of five years to hold office from the conclusion of the 20th Annual General Meeting till the conclusion of the 25th Annual General Meeting on such remuneration as may be decided by the Board and they continue to be the Statutory Auditors of the Company. Subsequently, pursuant to the recommendation of the Audit Committee, the Board of Directors, at its meeting held on 9th May, 2025, proposed the appointment of M/s. KKC & Associates LLP ("KKC"), Chartered Accountants (Firm Registration No. 105146W/ W100621), as Joint Statutory Auditors of the Company for a term of five consecutive years, commencing from the conclusion of the 23rd Annual General Meeting up to the conclusion of the 28th Annual General Meeting. The said appointment was duly approved by the shareholders at the Annual General Meeting held on 11th July, 2025.

The Notes on financial statements referred to in the Auditors' Report are self-explanatory and do not call for any further comments. The Auditor in their report

has not made any qualifications, reservations, or adverse remarks for the Financial Year 2025-26.

The Statutory Auditors of the Company have not reported any fraud as specified under the second proviso of Section 143(12) of the Companies Act, 2013 (including any statutory modification(s) or re- enactment(s) for the time being in force).

Pursuant to the provisions of Section 138 of the Act read with the Companies (Accounts) Rules, 2014, M/s. Varma & Varma, Chartered Accountants., were appointed as Internal Auditors to undertake internal audit of the Company for FY 2025-26.

The Internal Audit Report does not contain any qualification, reservation, or adverse remark.

The Internal Auditors of the Company have not reported any fraud as specified under the second proviso of Section 143(12) of the Companies Act, 2013 (including any statutory modification(s) or re-enactment(s) for the time being in force).

Pursuant to the provisions of Section 204 of the Act, read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and Regulation 24A of the Listing Regulations, M/s. Yogesh Sharma & Co. (CP No. 11305), Practicing Company Secretaries, were appointed as the Secretarial Auditor of the Company for a term of five years, commencing from FY 2025-26 to FY 2029-30 by the members of the Company at the Annual General Meeting held on 11th July, 2025.

The Secretarial Audit Report for FY 2025-26, as required under the aforesaid provisions, is appended herewith as Annexure IV and form parts of this report. The said report does not contain any qualification, reservation, or adverse remark.

The Secretarial Auditors of the Company have not reported any fraud as specified under the second proviso of Section 143(12) of the Companies Act, 2013 (including any statutory modification(s) or re- enactment(s) for the time being in force).

The Board of Directors of the Company has approved appointment of M/s. V. J. Talati & Co., Cost Accountant Firm, Mumbai (Membership No. M/26963) as the cost auditors to carry out auditing of cost records for the Financial Year 2026-2027. At a Remuneration of '1,80,000/- exclusive of taxes and reimbursement of out-of- pocket expenses incurred, if any, in connection with the cost audit subject to ratification by the members of the Company. The board of directors proposes ratification for the remuneration payable to

M/s. V. J. Talati & Co., Cost Accountants for cost audit for the financial year 2026-2027, at the ensuing Annual General Meeting.

The Cost Audit Report issued by the M/s. V. J. Talati & Co. for the financial year ended 31st March, 2026 does not contain any observation or qualification requiring explanation or comments from the Board under Section 134(3) of the Companies Act, 2013.

The Cost Auditors of the Company have not reported any fraud as specified under the second proviso of Section 143(12) of the Companies Act, 2013 (including any statutory modification(s) or re-enactment(s) for the time being in force).

Pursuant to the provisions of Section 148 of the Act, read with the Companies (Cost Records and Audit) Rules, 2014, as amended from time to time, the Company is required to maintain Cost Records under Rule 3 of the said Rules. Accordingly, the Company has duly maintained the Cost Records in the format prescribed under Rule 5 of the said Rules.

The Company is committed to conducting its affairs in a transparent manner, in compliance with applicable statutory requirements, and upholding the highest standards of professionalism and ethical conduct.

In line with the aforesaid commitment and in compliance with Section 177(9) of the Companies Act, 2013 read with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has established a Whistle Blower Policy, constituting a Vigil Mechanism. The Policy provides a formal mechanism for Directors and employees to report concerns relating to unethical conduct, actual or suspected fraud, or violation of the Company's Code of Conduct or ethics policies.

Further, in accordance with Regulation 9A of the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, the Company ensures that employees are made aware of the mechanism for reporting instances of leakage of Unpublished Price Sensitive Information (UPSI).

The Policy provides adequate safeguards against victimisation of persons who avail of the mechanism and also provides direct access to the Chairperson of the Audit Committee. It is hereby affirmed that no personnel have been denied access to the Audit Committee during the financial year 2025-26, and no such instances were reported.

The policy of vigil mechanism is available on the Company's website and can be accessed at: https:// www.jupiterhospital.com/Whistle-Blower-Policy.pdf

I n compliance with the requirements of Act and Rules made thereunder and pursuant to Regulation 19 of the SEBI Listing Regulations read with Schedule II Part D to the said Regulations, the Board of Directors has a Nomination and Remuneration Policy for its Directors, Key Managerial Personnel, Functional Heads and other employees of the Company.

The Salient features of the policy are as below:

• It aims to ensure fair and adequate remuneration for Directors, Key Managerial Personnel, and Senior Management Personnel.

• It adheres to legal requirements and promotes principles of integrity, performance-based rewards, and board diversity.

• The policy covers appointment criteria, term limits, evaluation criteria for directors, and guidelines for remuneration. It emphasises transparency and is effective immediately upon adoption.

During the year under review, there has been no change to the Policy.

The Nomination and Remuneration Policy of the Company is available on the website of the Company and can be accessed at the following web link: https:// www.iupiterhospital.com/thane/investor-relations/ corporate-governance/codes-and-policies/

The CSR Policy of the Company is guided by the Company's commitment to integrating social, environmental, and ethical responsibilities into its business governance, with a view to ensuring longterm success and sustainability.

In accordance with Section 135 of the Act, as amended read with the Notification Issued by the Ministry of Corporate Affairs and the rules made thereunder, the Company has formulated a Corporate Social Responsibility Policy, a brief outline of which, along with the required disclosures, is appended herewith as Annexure V and forms part of this Report.

The CSR Policy defines the governance framework for the planning, implementation, and oversight of the Company's CSR initiatives, along with the respective roles and responsibilities. It also sets out the criteria for selection of CSR projects, and the mechanisms for monitoring, evaluation, reporting, and disclosure of CSR activities.

The detail of the CSR Policy is also posted on the Company's website and may be accessed at: https:// www.jupiterhospital.com/CSR-Policy.pdf

The Company has adopted a Dividend Distribution policy in terms of Regulation 43A of SEBI Listing Regulations which is available on the Company's website can be accessed at: https://www.jupiterhospital. com/Dividend-Distribution-Policy.pdf.

The Company has constituted a Risk Management Committee consisting of Board Members who are authorised to monitor and review Risk Management plan. The Committee is also empowered, inter alia, to review and recommend to the Board the modifications to the Risk Management Policy. The Company has prepared a Risk Management policy to identify, evaluate the internal and external risks and opportunities in particular financial, operational, sectoral, sustainability (particularly, ESG related risks), information and cyber security risks.

The policy also includes the business continuity plan and the measures to be undertaken for risk mitigation including systems and processes for internal control of identified risks. Risk Management Policy enables the Company to proactively manage uncertainties and changes in the internal and external environment to limit negative impacts and capitalise on opportunities. The Company has laid down a comprehensive Risk Assessment and Minimisation Procedure in accordance with the requirements of the Act and the SEBI Listing Regulations, which is reviewed by the Risk Management Committee.

In terms of the applicable provisions of the SEBI Listing Regulations, your Board has adopted a Risk Management Policy, which is available on the Company's website at: https://www.jupiterhospital. com/Risk-Management-Policy.pdf

Information on Conservation of Energy, Technology absorption and Foreign Exchange earnings and outgo pursuant to Section 134(3)(m) of the Act, read with Rule 8(3) of the Companies (Accounts) Rules, 2014 is appended herewith as Annexure VI and forms part of this Report.

The statement containing particulars in terms of Section 197(12) of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 forms part of this Report and is appended herewith as Annexure VII and forms part of this Report.

The statement containing particulars in terms of Section 197(12) of the Companies Act, 2013 read with Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 forms part of this Annual Report. Considering the first proviso to Section 136(1) of the Companies Act, 2013, the Annual Report, excluding the aforesaid information, is being sent to the Members of the Company and others entitled thereto. The said information is available for inspection at the Registered Office of the Company during business hours on working days of the Company up to the date of the ensuing Annual General Meeting. Any shareholder interested in obtaining a copy thereof, may write to the Secretarial Team of the Company in this regard.

During the year under review, all contracts or arrangements or transactions entered by the Company with the Related Parties were in compliance with the applicable provisions of the Act and the SEBI Listing Regulations. All such contracts or arrangements, were entered into in the ordinary course of business and at arm's length basis and approved by the Audit Committee. Accordingly, the disclosure of related party transactions as required under Section 134(3)(h) read with Section 188 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014 of the Act in Form AOC-2 is not applicable. There were no related party transactions which could have potential conflict with the interests of the Company at large.

Details of related party transactions entered into by the Company, in terms of Ind AS-24 have been disclosed in the notes to the audited financial statements of the Company. The Company has in place a Related Party Transactions Policy, which is available on the Company's website at: https://www.jupiterhospital.com/Policy-on-Related-Party- Transactions.pdf.

All loans, guarantees, and investments made by the Company during the year under review have been made in accordance with Section 186 of the Companies Act, 2013 and have been duly disclosed in the Notes to the Financial Statements forming part of the Annual Report.

During the year under review, the Company has provided a corporate guarantee in favour of HDFC Bank Limited for the borrowing availed by Jupiter Hospital Projects Private Limited (JHPPL), its material subsidiary, for an amount not exceeding ' 250 Crores (Rupees Two Hundred Fifty Crores). The Company's guarantee shall be released upon either the repayment/ prepayment of 50% of the facility availed by JHPPL, or upon JHPPL achieving a Debt/EBITDA <3.5x for four consecutive quarters.

Internal Financial Controls: The Company has in place adequate internal financial controls with reference to its financial statements, aimed at safeguarding assets, preventing and detecting fraud or errors, maintaining accurate and complete accounting records, and ensuring the timely preparation of reliable financial information. Furthermore, statutory auditors have conducted comprehensive verifications of systems and processes, confirming the adequacy and operational effectiveness of internal financial controls over financial reporting. This ensures that the Company upholds strong corporate governance, financial transparency, and operational excellence.

The Directors have in the Directors Responsibility Statement confirmed the same to this effect.

The Company has obtained credit rating for bank facilities from ICRA Limited for the following long term and short-term borrowings and the same is available on website: https// www.jupiterhospital.com/investor-relations/investor- information/credit-rating/

The Company does not currently have an Employee Stock Ownership Plan (ESOP) scheme in place.

No public deposits have been accepted or renewed by your Company during the financial year under review pursuant to the provisions of Section 73 and 74 of the Act read together with the Companies (Acceptance of Deposits) Rules, 2014. Hence, the requirement for furnishing of details relating to deposits covered under Chapter V of the Act or the details of deposits which are not in compliance with Chapter V of the Act is not applicable.

As required by Section 134(3) of the Act, your Directors, to the best of their knowledge and belief, confirm that:

1. I n the preparation of the annexed accounts for the Financial Year ended 31st March, 2026, all the applicable accounting standards have been followed along with proper explanation relating to material departures, if any;

2. Your directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs and of the profit of the Company at the end of the Financial Year 2025-26;

3. Your directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

4. The said accounts have been prepared on a going concern basis;

5. Proper internal financial controls laid down by the Directors were followed by the Company and that such internal financial controls are adequate and were operating effectively; and

6. Proper systems to ensure compliance with the provisions of all applicable laws have been devised and that such systems are adequate and operating effectively.

Your Company has adopted a Policy on Prevention, Prohibition and Redressal of Sexual Harassment at the workplace, in line with the requirements of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules made thereunder. Your Company has also constituted Internal Complaints Committees (ICC) to address and redress complaints in this regard.

Accordingly, during the financial year under review:-

(i) Number of complaints of sexual harassment received during the year - NIL

(ii) Number of complaints disposed of during the year - Not Applicable

(iii) Number of cases pending for more than ninety days - NIL

There have been no significant material orders passed by Regulators, Courts, or Tribunals that would impact the going concern status of the Company and its future operations. Furthermore, there have been no material changes or commitments that could affect the financial position of the Company between the end of the Financial Year to which the Financial Statements relate and the date of this report.

During the year under review there were no significant / material orders passed by the Courts or Regulators or Tribunals impacting the going concern status and operations of the Company in the future.

The maternity benefits provided by your Company offer financial security, job protection, and adequate time for rest and recovery to female employees during and after childbirth or adoption.

By complying with the provisions of the Maternity Benefit Act, 1961, the Company ensures a supportive and inclusive work environment that promotes the well-being of both the employee and her child

The Company has complied with the Secretarial Standards i.e. SS-1 and SS-2, relating to 'Meetings of the Board of Directors' and 'General Meetings', respectively issued by the Institute of Company Secretaries of India.

As required under Section 92(3) of the Act, Annual Return is hosted on the website of the Company at https://www. jupiterhospital.com/thane/investor-relations/annual- report/annual-return/

Your directors state that: -

(i) There are no instances of fraud reported by the Auditors under Section 143(12) during the financial year ended 31st March, 2026.

(ii) The Company has not issued any shares with differential voting rights as per the Act.

(iii) The Company has not issued any sweat equity shares under the Act.

(iv) There were no instances of non-exercising of voting rights in respect of shares purchased directly by employees under a scheme pursuant to Section 67(3) of the Act read with Rule 16(4) of Companies (Share Capital and Debentures) Rules, 2014

(v) There are no applications made or any proceedings pending under the Insolvency and Bankruptcy Code, 2016 (31 of 2016) during the financial year.

(vi) The requirement to disclose the details of difference between amount of the valuation done at the time of onetime settlement and the valuation done while taking loan from the Banks or Financial Institutions along with the reasons thereof, is not applicable.

(vii) The Company has not accepted any fixed deposits and no amount of principal or interest is outstanding during the year ended 31st March, 2026.

Your Company has continued to operate efficiently and responsibly, driven by a strong culture of professionalism, integrity, ethics, good governance, and continuous improvement across all functions, along with optimal utilisation of resources to achieve sustainable and profitable growth.

Your directors would like to express their sincere appreciation to its stakeholder's, financial institutions, bankers and business associates, Government authorities, customers and vendors for their co-operation and support and looks forward to their continued support in future. Your directors also place on record, their deep sense of appreciation for the committed services by the employees of the Company.